Phase 1 Evaluation of HMPL-306 in Patients with IDH-Mutant Locally Advanced or Metastatic Solid Tumors, Including Cholangiocarcinoma, Chondrosarcoma, and Glioma

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of **HMPL-306** in patients with locally advanced or metastatic solid tumors harboring **IDH mutations**. This includes conditions such as cholangiocarcinoma, skeletal chondrosarcoma, low-grade glioma, and other solid tumors with these mutations. Understanding the safety profile of HMPL-306 is clinically relevant as it may offer a new therapeutic option for patients with these specific genetic alterations, potentially improving treatment outcomes and expanding available therapies for these challenging malignancies.

The clinical trial involves a total of **18 participants** diagnosed with **locally advanced or metastatic solid tumors**, including specific conditions such as **cholangiocarcinoma**, **skeletal chondrosarcoma**, **low-grade glioma**, and any other solid tumor with an **IDH mutation**. The study population comprises both male and female subjects, with an age range that includes both adults and adolescents. Participants were selected based on the presence of the specified medical conditions, and the trial includes a vulnerable population. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective or specific inclusion criteria for the study.

The clinical trial is a **Phase 1** study designed to evaluate the safety and efficacy of HMPL-306 in patients with **locally advanced or metastatic solid tumors** harboring **IDH mutations**. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The estimated duration of the trial spans from February 9, 2021, to June 5, 2025, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a thorough review of the participant's medical history, physical examination, and necessary laboratory tests to confirm the presence of an **IDH mutation**. Following successful screening, participants will be enrolled in the study and randomized to receive either the investigational product or a control. Regular follow-up visits will be scheduled to monitor the participants' health, assess treatment response, and document any adverse events. These visits are critical for ensuring participant safety and collecting data on the investigational product's efficacy.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, a final assessment will be conducted to evaluate the overall impact of the treatment. The expected length of participant involvement will vary depending on individual response to treatment and the occurrence of any adverse events. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The trial's design and procedures are meticulously planned to ensure the collection of reliable and valid data, contributing to the understanding of HMPL-306's potential therapeutic benefits in treating solid tumors with **IDH mutations**.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be described. The data does not include any information about the **disease** being studied, the trial's main objective, or the role of any products involved in the trial. Consequently, a comprehensive description of the treatments used in this clinical trial cannot be constructed based on the current dataset.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on February 9, 2021, with an estimated completion date of June 5, 2025. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methodology for measuring and analyzing efficacy will adhere to the standards expected in a Phase 3 clinical trial, ensuring robust and reliable results. The trial's design and execution will be aligned with regulatory requirements and scientific rigor to accurately determine the efficacy of the investigational product.